Cloyd JM, Norton JA, Visser BC, Poultsides GA. Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases. Ann Surg Oncol. 2015;22(2):573–80.
Article
Google Scholar
Meijer LL, Alberga AJ, de Bakker JK, van der Vliet HJ, Le Large TYS, van Grieken NCT, et al. Outcomes and treatment options for duodenal adenocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25(9):2681–92.
Article
Google Scholar
Solej M, D'Amico S, Brondino G, Ferronato M, Nano M. Primary duodenal adenocarcinoma. Tumori. 2008;94(6):779–86.
Article
Google Scholar
Koornstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in Lynch syndrome: is it time for surveillance? Lancet Oncol. 2008;9(9):901–5.
Article
Google Scholar
Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126(2):394–401.
Article
CAS
Google Scholar
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.
Article
Google Scholar
Ishida H, Yamaguchi T, Tanakaya K, Akagi K, Inoue Y, Kumamoto K, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the clinical practice of hereditary colorectal cancer (translated version). J Anus Rectum Colon. 2018;2(Suppl.1):S1–51.
Article
Google Scholar
Sakae H, Kanzaki H, Nasu J, Akimoto Y, Matsueda K, Yoshioka M, et al. The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer. 2017;117(11):1607–13.
Article
Google Scholar
Jigyasu D, Bedikian AY, Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer. 1984;53(1):23–5.
Article
CAS
Google Scholar
Ono M, Shirao K, Takashima A, Morizane C, Okita N, Takahari D, et al. Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer. 2008;11(4):201–5.
Article
CAS
Google Scholar
Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10(2):132–7.
Article
CAS
Google Scholar
Delaunoit T, Neczyporenko F, Limburg PJ, Erlichman C. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol. 2005;100(3):703–10.
Article
Google Scholar
Haan JC, Buffart TE, Eijk PP, van de Wiel MA, van Wieringen WN, Howdle PD, et al. Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers. Ann Oncol. 2012;23(2):367–74.
Article
CAS
Google Scholar
Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010;102(1):144–50.
Article
CAS
Google Scholar
Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27(16):2598–603.
Article
CAS
Google Scholar
Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F, Zhan ZY, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anti-Cancer Drugs. 2012;23(5):561–6.
Article
CAS
Google Scholar
Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: a single-center, open-label, phase 2 study. Cancer. 2017;123(6):1011–7.
Article
CAS
Google Scholar
McWilliams RR, Foster NR, Mahoney MR, Smyrk TC, Murray JA, Ames MM, et al. North central cancer treatment group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 2017;123(18):3494–501.
Article
CAS
Google Scholar
Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol. 2012;13(11):1125–32.
Article
CAS
Google Scholar
Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141–8.
Article
CAS
Google Scholar
Onkendi EO, Boostrom SY, Sarr MG, Farnell MB, Nagorney DM, Donohue JH, et al. Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy. J Gastrointest Surg. 2012;16(2):320–4.
Article
Google Scholar
Kelsey CR, Nelson JW, Willett CG, Chino JP, Clough RW, Bendell JC, et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1436–41.
Article
Google Scholar
Manfredi S, Thiebot T, Henno S, Falize L, Bretagne JF, Meunier B. Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen. J Gastrointest Surg. 2009;13(12):2309–13.
Article
Google Scholar
Hamad A, Singhi AD, Bahary N, McGrath K, Amarin R, Zeh HJ, et al. Neoadjuvant treatment with trastuzumab and FOLFOX induces a complete pathologic response in a metastatic ERBB2 (HER2)-amplified duodenal cancer. J Natl Compr Cancer Netw. 2017;15(8):983–8.
Article
Google Scholar
Zhang GY, Mao J, Zhao B, Long B, Zhan H, Zhang JQ, et al. Duodenal bulb adenocarcinoma benefitted from Neoadjuvant chemotherapy: a case report. Chemotherapy. 2017;62(5):290–4.
Article
Google Scholar
Velandia C, Morales RD, Coello C, Mendoza AG, Perez G, Aguero E. Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma. Ecancermedicalscience. 2018;12:816.
Article
Google Scholar
Hagihara S, Shimizu T, Inoue Y, Asakuma M, Hirokawa F, Taniguchi K, et al. A complete response to capecitabine and oxaliplatin chemotherapy in primary duodenal carcinoma with liver and nodal metastases: a case report. Surg Case Rep. 2018;4(1):125.
Article
Google Scholar
Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21(9):1786–93.
Article
CAS
Google Scholar
Tsushima T, Taguri M, Honma Y, Takahashi H, Ueda S, Nishina T, et al. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist. 2012;17(9):1163–70.
Article
CAS
Google Scholar
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Small bowel adenocarcinoma, version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(9):1109–33.
Article
Google Scholar
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
Article
CAS
Google Scholar
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.
Article
CAS
Google Scholar